H10 — Clomiphene dose–urate coupling

Evidence status: Pending. Overall tier: Mechanistic Extrapolation plus a disclosed n=1 longitudinal signal. No direct study has established that clomiphene raises serum urate or causes gout.

Claim

In a susceptible clomiphene-treated phenotype with laboratory-high androgen exposure, sustained clomiphene exposure and same-assay venous serum urate are positively coupled: a clinician-directed exposure reduction that produces an adequate hormone contrast will be followed at steady state by a reproducible urate decrease, and the urate change will covary with the hormone change. The 0.5 mg/dL threshold below is the project's pre-committed relevance threshold for an Alive result, not the definition of positive coupling.

This claim does not specify renal, intestinal, estrogen-receptor, or androgen-receptor dominance. Those are competing mechanisms to be separated only after the exposure–urate relationship is established.

Hypothesis-generating case signal

The following observations are disclosed from the project lead's longitudinal record. The underlying health files remain private and are not independently auditable; these observations are not independent clinical evidence.

Observation	Record	Interpretation limit
Clomiphene exposure began	25 mg daily on 2022-12-12	No pre-exposure serum urate measurement was recorded.
Hormone state after initiation	Total testosterone 1,226 ng/dL and estradiol 60 pg/mL on 2023-01-31	Confirms a laboratory-high hormone response; it does not establish a urate response.
Podagra timing	Symptoms began 2023-02-16, about 9.5 weeks after initiation; the first documented gout visit was 2023-02-20	The clinician recorded vague prior mild episodes of “the same thing,” but the project lead does not recall them and no corroborating earlier record was found. Treat this as the first documented episode; whether it was the first-ever symptom is unresolved.
Pre-reduction state	Venous urate 8.0 mg/dL, total testosterone 1,210 ng/dL, free testosterone 23.8 ng/dL, and estradiol 54.8 pg/mL on 2026-04-09	One cross-sectional panel cannot assign causality.
Exposure reduction	Approximately 50% lower weekly clomiphene exposure beginning 2026-04-25	This was an uncontrolled personal dose change, not a blinded experiment.
Flare after reduction	One left first-MTP flare began 12 days later	A flare during a changing urate pool is compatible with several directions and does not prove that serum urate fell.
Urate after reduction	Home capillary readings of 7.2 and 7.3 mg/dL on 2026-05-22 and 2026-06-03	These are suggestive of a small decrease but are not quantitatively comparable with the earlier venous laboratory value without paired device calibration.
Joint observation	By July 2026, the visible left first-MTP prominence appeared smaller by self-observation	The prominence has not been confirmed as a tophus by aspiration or imaging and could include bunion anatomy; visible change is not a validated crystal-burden measurement.

Published evidence boundary

• Androgen–urate prior — supported. Yahyaoui et al. prospectively followed 69 people before and after cross-sex hormone therapy. In the 47-person transmasculine group, mean serum urate rose from 3.91 mg/dL at baseline to 5.07 at one year and remained 5.02 at two years; in the 25-person FEUA subgroup, mean fractional excretion fell from 8.78% to 6.93% at two years (P = 0.004; PMID 18349066, Table 1). Kurahashi et al. independently observed serum-urate elevation after three months of testosterone therapy in 160 transmasculine participants, with a tendency toward dose dependence (DOI 10.1507/endocrj.EJ13-0203). Androgen deprivation produced a reverse-direction urate signal in men with prostate cancer (PMID 30557349). Human prospective/observational intervention evidence — non-randomized, not Clinical Trial tier. Mouse renal-transporter data add Animal Model support (PMID 20589576). This is a substantive prior for hormone-sensitive urate biology and renal handling, not a universal testosterone rule.
• Clomiphene-specific effect — unmeasured. No study located prospectively measured serum urate, urate handling, incident gout, or dose response after clomiphene initiation or dose reduction. Male safety publications did not track those endpoints (PMIDs 32233208, 34933414, 31216250, 22458540). The US label and three non-primary-suspect openFDA gout co-reports do not resolve chronic male risk. H10 therefore remains Mechanistic Extrapolation plus a disclosed n=1 signal; the testosterone direction cannot be imported as a clomiphene result.
• Recorded topical salicylic-acid exposure — weak alternative. The acute visit record documents treatment of two plantar warts with topical salicylic acid before the first documented flare. Systemic low-dose aspirin was associated with recurrent attacks in people with established gout (PMID 23345599), so salicylate exposure is not biologically irrelevant. An exact PubMed search found no study connecting topical salicylic acid with urate or gout. In four patients with active psoriasis, repeated large-area occlusive treatment absorbed more than 60% of the applied acid while serum salicylate remained at or below 5 mg/100 mL (PMID 1094962); a severe intoxication case used 40% ointment over approximately 41% of body surface area (PMID 1424799). These observations establish exposure dependence, not zero absorption at small areas. The recorded two-wart exposure is therefore a weak, unquantified Mechanistic Extrapolation, not an evidence-backed alternative cause.
• Intestinal ER/ABCG2 mechanism — unsupported. No direct human-enterocyte, intestinal-flux, or exposure-relevant stereoisomer study establishes this chain. H07 remains retracted. Renal handling, urate production, intestinal transport, and mixed mechanisms remain open until a clomiphene-specific effect is measured.

Competing explanations

1. Pre-existing hyperuricemia or silent crystal burden may have produced the documented flare independently of clomiphene. Dual-energy CT has documented silent monosodium urate deposition in asymptomatic hyperuricemia (PMID 25637002), supporting an unmasking alternative.
2. The documented limited-area topical salicylic-acid exposure remains an unmeasured alternative. Available evidence does not justify transferring systemic aspirin risk or extensive-dermatologic-exposure data directly to two treated warts, and no contemporaneous serum salicylate or urate measurement exists.
3. Diet, alcohol, hydration, weight, renal function, illness, and concurrent interventions can move urate or flare risk over the same intervals.
4. Clomiphene changes testosterone, estradiol, SHBG, and receptor signaling together; any net urate effect may be nonlinear or person-specific.
5. The pre/post urate values use different measurement systems and do not establish an effect size.
6. A post-reduction flare is not a directional biomarker, and the visible joint change is neither imaging-confirmed nor specific to urate deposition.

Discriminating tests

No experiment should require a participant to change a clinically indicated medication solely for this hypothesis. The lowest-cost valid test observes clinician-directed changes prospectively.

1. Collect two same-laboratory venous panels 7–14 days apart before a clinically directed exposure change and two panels 7–14 days apart after the new exposure state is stable. Each panel includes serum urate, total testosterone, sensitive estradiol, SHBG, creatinine or cystatin C, and paired urine urate/creatinine.
2. Repeat each steady-state venous urate measurement so that any change can be judged against analytical and within-person variability. Calibrate a home meter with paired venous/capillary samples if capillary trends are used between visits.
3. Separate renal handling with fractional excretion of urate. A urate change with concordant FEUA change supports renal involvement; unchanged FEUA leaves production and intestinal disposal open.
4. Test the population claim in a prospective clomiphene cohort with baseline and follow-up urate, hormones, renal function, flare history, and major dietary or medication confounders prespecified.
5. Test intestinal ER or stereoisomer mechanisms only in direct enterocyte experiments with clomiphene, enclomiphene, and zuclomiphene at exposure-relevant concentrations.

Pre-committed outcomes

These are project decision thresholds, not published clinical minimum-important differences.

• Adequate exposure contrast: mean total testosterone or calculated free testosterone changes by at least 20% between the two pre-change and two post-steady-state panels.
• Major-confounder rule: eGFR remains within 10% and body mass within 3%; no urate-lowering drug, diuretic, SGLT2 inhibitor, systemic glucocorticoid, or other prespecified urate-active medication is started, stopped, or dose-changed; no acute illness occurs; and the standardized seven-day alcohol and high-purine-food logs differ by no more than 20% in mean daily servings between exposure states. A transition outside any bound remains Pending.
• Within-person Alive threshold: mean same-laboratory venous serum urate changes by at least 0.5 mg/dL in the predicted direction, with both post-steady-state values below the pre-change mean and the exposure-contrast and confounder rules satisfied. One qualifying transition supports this susceptible-phenotype card but does not establish a population effect.
• Within-person Killed threshold: two adequately measured clinician-directed exposure transitions each produce less than 0.2 mg/dL absolute change in mean venous urate, or either produces an opposite-direction change of at least 0.5 mg/dL, under the same renal-stability and confounder rules.
• Population threshold: before enrollment, power the paired analysis to detect a 0.5 mg/dL within-person urate change at 80% power and two-sided α=0.05 using variance from the study population. Population-level Alive requires an adjusted mean paired reduction of at least 0.5 mg/dL with a 95% confidence interval excluding zero. Population-level Killed applies when the upper 95% confidence bound is below a 0.2 mg/dL reduction or the interval is wholly in the opposite direction. Estimates compatible with a positive 0.2–0.5 mg/dL reduction remain Pending.
• Pending: mixed, unpaired, cross-assay, underpowered, or confounded observations—including the current record—do not change status.

Execution log

Date	Test	Outcome	Notes
2026-07-17	Existing longitudinal record	Pending	Temporal signal is coherent but lacks pre-initiation urate, paired same-assay dechallenge measurements, imaging confirmation, and confounder control.